- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Case Study Spotlights FCS as a Top-Ranking Performer in the Oncology Care Model
A recently published case study by Florida Cancer Specialists & Research Institute showcased the practice’s multi-year track record of delivering savings as a participant in the Oncology Care Model (OCM) when compared with OCM and non-OCM practices nationally.
Fort Myers, Florida — A recently published case study by Florida Cancer Specialists & Research Institute (FCS) showcased the practice’s multi-year track record of delivering savings as a participant in the Oncology Care Model (OCM) when compared with OCM and non-OCM practices nationally.
Amongst more than 125 participating practices nationwide, FCS emerged as a leader in value-based care oncology in having successfully reduced Medicare expenditures by nearly $170 million in aggregate.
“Our success in this program is indicative of the resources, dedication, investment and overall integrity of FCS’ commitment to healthcare reform,” said Michael Diaz, MD, president and managing physician, FCS. “Patients can find reassurance knowing that we have put elaborate measures in place to not only utilize state of the art technologies and therapeutics to maximize treatment outcomes but optimize care delivery to positively influence their overall cancer journey.”
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
